segment depression on admission, even in the context of these expanded biomarker profiles. 4 Lead aVR, a frequently ignored lead, 15 has not been considered in most previous studies assessing the prognostic role of ECG in patients with NSTE-ACS. However, several studies have found that ST-segment elevation in lead aVR on the admission ECG (ST aVR) offers better prognostic information than ST-segment depression in leads other than aVR in patients with NSTE-ACS. [16] [17] [18] ST aVR has been shown to be superior to ST-segment depression in other leads for predicting the risk of death in patients with non-ST-segment elevation acute myocardial infarction. 16 We have also previously shown that ST aVR is more strongly associated with left main and/or 3-vessel coronary disease and subsequent adverse events than ST-segment depression in other leads in patients with NSTE-ACS. 17, 18 However, the prognostic impact of ST-segment elevation resolution in lead aVR has yet to be investigated, so the present study was designed to investigate the relation of ST-segment elevation resolution in lead aVR to angiographic findings and to 30-day outcomes in patients with NSTE-ACS.
Methods
volving an unstable pattern of pain, consisting of rest pain, new onset, severe or frequent angina, or accelerating angina; (2) no conditions precluding the evaluation of ST-segment changes on the ECG (left or right bundle branch block, left ventricular hypertrophy, digitalis glycoside therapy, or ventricular pacing); (3) fully assessable ECGs on admission and 6 h after admission; and (4) fully assessable angiographic data during hospitalization. Patients with nonischemic or atypical symptoms, persistent new ST-segment elevation in leads other than aVR, or a recent history (<6 months) of percutaneous coronary intervention were excluded. In our hospital, we perform emergency cardiac catheterization and revascularization immediately after admission in patients with unstable hemodynamics because of ischemic attacks and in those in whom ischemic attacks cannot be controlled by intensive drug treatment (particularly patients with decreased cardiac function). In other patients, drug treatment is given after admission to stabilize their condition, and cardiac catheterization is performed a median of 3 days after admission. In patients with indications for revascularization, it is performed later. Urgent cardiac catheterization and revascularization are performed in patients with repeated episodes of angina or hemodynamic instability despite intensive drug therapy. In our study, patients who underwent emergency revascularization within 6 h after admission were excluded. Aspirin, intravenous heparin, and nitrates were administered to most patients. Other clinically indicated medications were used at the discretion of the treating physician. The physicians obtained informed consent from each patient, and the study was approved by the hospital ethics committee.
ECG Analysis
Standard 12-lead ECGs were recorded on admission and 6 h after admission at a paper speed of 25 mm/s and an amplification of 10 mm/mV. All ECGs were examined by a single cardiologist who was unaware of all other clinical data. ST-segment shifts were measured 80 ms after the J point for ST-segment depression and 20 ms after this point for ST-segment elevation, using the preceding TP segment as baseline. 12 ST-segment deviation was considered present if deviation was ≥0.5 mm in any lead. 6, 16 
Biomarker Analysis
Blood samples for measurement of plasma CRP levels were taken on admission. High-sensitivity CRP levels were measured by N Latex CRP Mono tests in a Behring BN II Nephelometer (Behring Diagnostics, Tokyo, Japan) using polystyrene microbeads coated with monoclonal mouse antibodies. 19 In addition, a qualitative assay for cardiac-specific troponin T (Roche Diagnostics, Tokyo, Japan; detection limit, 0.1 ng/ml of cardiac-specific troponin T) was simultaneously performed. A troponin T level ≥0.1 ng/ml was defined as positive. The test was repeated at 8-12 h in patients who were negative for troponin T within 6 h after the onset of symptoms. Levels of creatine kinase MB isoenzyme (CK-MB) were determined on admission, at 3-h intervals during the first 24 h, and in any patient with suspected reinfarction.
Angiographic Analysis
All patients underwent cardiac catheterization at a median of 3 days after admission. All coronary angiograms were evaluated by a single cardiologist who was unaware of all other clinical data. Stenosis ≥50% in the diameter of the left main coronary artery or ≥75% in 1 or more of the major epicardial vessels or their main branches was considered as clinically significant.
Clinical Data Collection
All patients were followed up for 30 days after admission to hospital. Major adverse events were defined as death, myocardial (re)infarction, or urgent revascularization within 30 days after admission. Myocardial (re)infarction was diagnosed on the basis of either enzyme or ECG evidence. Enzyme evidence of re-infarction was defined as a reelevation of the CK-MB level to higher than the upper limit of normal if the previous level was in the normal range, or as 50% above the previous level if the previous level was higher than the upper limit of normal.
Statistical Analysis
Continuous data are expressed as means ± SD, and categorical data are expressed as percentages. Analysis of variance was used to calculate p-values for continuous variables. Chi-square analysis was used to compare categorical variables. Differences were considered statistically significant at p<0.05. Event-free curves were generated by the Kaplan-Meier method and compared by the log-rank test. We used Cox proportional-hazards regression analysis to calculate adjusted hazard ratios and 95% confidence intervals for major predictors of adverse events (defined as death, myocardial [re]infarction, or urgent revascularization within 30 days after admission) among the variables associated (p≤ 0.20) with these endpoints on univariate analysis. Data were analyzed using SAS version 8.2 (SAS Institute, Cary, NC, USA) and SPSS version 12.0 (SPSS Inc, Chicago, IL, USA).
Results
In total, 92 patients had ST aVR, and 275 did not. Among the patients with ST aVR, 50 had ST resolution, defined as a reduction >50% in the degree of ST-segment elevation in lead aVR from admission to 6 h later, and 42 did not.
Patients' Characteristics
The baseline clinical characteristics of the patients, according to ST-segment status in lead aVR, are shown in Table 1 . Patients who had ST aVR without ST resolution were older and had higher rates of using -blockers and nitrates before admission and intravenous nicorandil in hospital, Killip class ≥2 on admission, and positive troponin T, as well as a higher level of CK-MB on admission. Heart rate on admission was higher in patients with ST aVR. There was a trend toward a lower rate of men, a higher rate of diabetes mellitus, and a higher level of high-sensitivity CRP on admission in patients who had ST aVR without ST resolution, but the differences did not reach statistical significance. There were no significant differences in prior myocardial infarction, prior revascularization, hypertension, symptom onset ≤6 h, or systolic blood pressure on admission among the 3 groups. Coronary artery bypass surgery was more frequently performed during hospitalization in patients who had ST aVR without ST resolution. The rates of revascularization procedures during hospitalization were higher in patients with ST aVR, especially those without ST resolution.
ECG Findings
The ECG findings according to ST-segment status in lead aVR are shown in Table 2 . On the admission ECG, all patients with ST aVR had ST-segment depression in leads 
Angiographic Findings and Cardiac Procedures During Hospitalization
The angiographic findings of the patients according to the ST-segment status in lead aVR are shown in Table 2 . Patients with ST aVR, especially those without ST resolution, had a higher rates of multivessel disease and left main and/or 3-vessel coronary disease. In particular, the rates of severe left main and/or 3-vessel coronary disease, defined as 75% stenosis of the left main coronary artery and/or 90% stenosis in 2 proximal lesions of the major epicardial vessels, were much higher in patients who had ST aVR without ST resolution (Fig 1) .
Predictors of 30-Day Outcome
Patients with ST aVR without ST resolution had higher rates of death, (re)infarction, or urgent revascularization within 30 days after admission ( Table 3 , Fig 2) . In the multivariate models, ST aVR without ST resolution was the strongest predictor of restricted events (death or [re]infarction) and the composite endpoint (death, [re]infarction, or urgent revascularization) at 30 days, followed by positive troponin T ( Table 4 ). The other variables associated with these endpoints on univariate analysis, including age, sex, Killip class, high-sensitivity CRP, CK-MB, the magnitude of ST-segment elevation in lead aVR on admission and 6 h later, and the sum of ST-segment depression on the admission and 6 h later, were not significant predictors of these endpoints. ST aVR with ST resolution was also not a significant predictor of these endpoints.
Discussion
To the best of our knowledge, this is the first study to examine the prognostic value of ST-segment elevation resolution in lead aVR in patients with NSTE-ACS. We found that ST aVR without ST resolution (ie, persistent ST-segment elevation in lead aVR) was the strongest predictor of adverse outcomes at 30 days and was closely associated with the extent and severity of underlying coronary artery disease in patients with NSTE-ACS. In contrast, ST aVR with ST resolution (ie, transient ST-segment elevation in lead aVR) was not significantly associated with 30-day outcomes. These findings suggest that analysis of the ST-segment changes in lead aVR after admission can facilitate risk stratification in patients with NSTE-ACS.
Possible Mechanisms of ST-Segment Elevation in Lead aVR
Acute coronary syndromes are categorized into ST-segment elevation myocardial infarction and NSTE-ACS. The mechanism underlying ST-segment elevation in lead aVR may differ between these 2 conditions. In ST-segment elevation myocardial infarction, ST-segment elevation in lead aVR may reflect transmural ischemia in the dominant basal septum, often caused by left-main obstruction or obstruction of the proximal left anterior descending coronary artery with involvement of the first septal branch, 20, 21 resulting in a superior orientation of the ST-segment vector. 15 In NSTE-ACS, ST-segment elevation in lead aVR may reflect global subendocardial ischemia. Lead aVR has the unique position of "looking" into the left ventricular cavity from the right shoulder. 22 In circumferential ischemia, often associated with left main or 3-vessel disease, accompanied by a sudden dramatic increase in left ventricular end-diastolic pressure and severe extensive ischemia of the subendocardial layer, 6 the ST-segment vector is directed to the right, resulting in ST-segment elevation in lead aVR. We and other investigators have shown that ST-segment elevation in lead aVR is closely associated with left main and/or 3vessel disease in patients with NSTE-ACS. 5, [16] [17] [18] In the present study, the frequency of ST-segment elevation in lead aVR on the admission ECG was 25%, as compared with 7-33% in previous studies. 5, [16] [17] [18] The frequency of ST-segment elevation in lead aVR may differ according to disease severity on coronary angiography, which varies depending on the type of study and inclusion criteria for patients.
Persistent ST-Segment Elevation in Lead aVR After Admission
Kaul et al 9 showed that the persistence of ST-segment depression beyond 6 h after symptom onset was more associated with a 3-fold higher risk of death or myocardial infarction at 6 months than was the resolution of ST-segment depression within 6 h in patients with NSTE-ACS. This finding suggests that prolonged ST-segment depression correlates with worse outcomes. We have also previously demonstrated that persistent ST-segment depression 6 h after admission is associated with multivessel disease and 30day adverse events in patients with NSTE-ACS, but did not consider lead aVR in that study. 23 We subsequently showed that ST-segment elevation in lead aVR on admission is more strongly associated with left main and/or 3-vessel coronary disease and subsequent adverse events than is ST-segment depression in other leads in patients with NSTE-ACS. 17, 18 The present study confirms and extends our previous findings by showing that persistent ST-segment elevation in lead aVR was closely associated with "severe" left main and/or 3-vessel disease and a strikingly higher risk of 30-day adverse events in patients with NSTE-ACS. In patients who had persistent ST-segment elevation in lead aVR, severe and prolonged myocardial ischemia refractory to medical treatment, associated with more severe and unstable coronary artery disease, might have contributed to the lack of ST resolution. Consequently, urgent coronary artery bypass graft surgery was more frequently performed in these patients. Early identification of patients with left main and/or 3-vessel disease who require surgical revascularization is crucial for deciding whether early treatment with clopidogrel should be initiated. Because combined antiplatelet therapy with aspirin and clopidogrel improves outcomes in patients with NSTE-ACS, 24 ,25 the addition of clopidogrel to aspirin on admission has been recommended. 3 However, such combination therapy can increase the risk of major bleeding in patients undergoing early coronary artery bypass graft surgery within 5 days after the withdrawal of clopidogrel. 26, 27 Therefore, some have recommended that clopidogrel not be given until after angiography to avoid an increased risk of bleeding in patients likely to require immediate surgery. 28 However, this recommendation is not included in the European Society of Cardiology guidelines, because such patients are relatively uncommon and surgery can frequently be deferred for several days. 28 Nonetheless, postponing treatment with clopidogrel may be advantageous in selected patients who require immediate surgery. The American College of Cardiology/American Heart Association (ACC/AHA) guidelines for the management of NSTE-ACS recommend early invasive management for high-risk patients; 3 however, a meta-analysis of randomized clinical trials 29 showed no incremental improvement in outcomes when angiography was performed within 24 h. Our results suggest that early coronary angiography can be expedited by postponing clopidogrel in patients with persistent ST-segment elevation in lead aVR who are likely to need immediate surgical revascularization.
ST-Segment Elevation in Lead aVR vs ST-Segment Depression in Other Leads
Several clinical trials have demonstrated the prognostic importance of the magnitude of ST-segment depression in patients with NSTE-ACS. [6] [7] [8] [9] In our study, persistent ST-segment elevation in lead aVR was associated with a greater degree of ST-segment depression on admission and 6 h later. However, multivariate analysis showed that persistent ST-segment elevation in lead aVR per se, apart from the magnitude of ST-segment depression, was related to adverse outcomes. We and other investigators have found that STsegment elevation in lead aVR on admission offers better prognostic information than ST-segment depression in other leads in patients with NSTE-ACS. 5, [16] [17] [18] 
Study Limitations
This study was retrospective, performed at a single center, and included a small number of patients who underwent coronary angiography during hospitalization. Moreover, we examined the prognostic implications of ST-segment elevation in lead aVR only with respect to 30-day outcomes. However, in the GUSTO-IV trial of 7,800 patients with NSTE-ACS, ST-segment depression on admission had a greater prognostic impact on mortality at 30 days than on mortality at 1 year. The prognostic value of ST-segment depression on admission thus appears to be higher for outcomes at 30 days. 4 Furthermore, the rate of either death or (re)infarction was low overall in our study, which may reflect genetic and environmental differences between Japan and other countries or a higher rate of revascularization during hospitalization. Further studies in larger numbers of patients are needed to verify the prognostic impact of STsegment elevation in lead aVR.
Conclusion
ST-segment elevation in lead aVR 6 h after admission provides very useful information about the need for more aggressive treatment and the extent and severity of underlying coronary artery disease, and can be used to predict outcomes in patients with NSTE-ACS. The predictive power of this simple, readily available, and noninvasive prognostic factor is very strong, facilitating the timely triage of patients to appropriate therapeutic interventions.
